Giuseppe Valenti

Palermo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Expert consensus on the Management of Mild and Moderate Asthma.

Expert consensus on the Management of Mild and Moderate Asthma.

Journal: Respiratory medicine

Published: May 29, 2026

Pollen-induced asthma: diagnostic and therapeutic implications.

Pollen-induced asthma: diagnostic and therapeutic implications.

Journal: European annals of allergy and clinical immunology

Published: September 02, 2025

Biologic Therapy Timing and Severe Asthma Progression: Insights from the Italian Registry on Severe Asthma.

Biologic Therapy Timing and Severe Asthma Progression: Insights from the Italian Registry on Severe Asthma.

Journal: Respiration; international review of thoracic diseases

Published: July 22, 2025

Sex-Based Comparison of Remission in Patients with Severe Type 2 Asthma Treated with Biologics: A Real-World Analysis from the "Southern Italy Network on Severe Asthma Therapy".

Sex-Based Comparison of Remission in Patients with Severe Type 2 Asthma Treated with Biologics: A Real-World Analysis from the "Southern Italy Network on Severe Asthma Therapy".

Journal: Respiration; international review of thoracic diseases

Published: June 25, 2025

Pollen-induced asthma: a specific pheno-endotype of disease?

Pollen-induced asthma: a specific pheno-endotype of disease?

Journal: European annals of allergy and clinical immunology

Published: May 13, 2025

Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab.

Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: April 09, 2024

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.

Journal: The journal of allergy and clinical immunology. In practice

Published: March 14, 2024

Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.

Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.

Journal: Respirology (Carlton, Vic.)

Published: January 10, 2024

Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.

Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.

Journal: Frontiers in immunology

Published: November 23, 2023

Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Journal: ERJ open research

Published: June 26, 2023

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.

Journal: Journal of clinical medicine

Published: May 29, 2023

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.

Journal: Frontiers in immunology

Published: April 12, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026